4.3 Article

Carvedilol Reduces Aortic Wave Reflection and Improves Left Ventricular/Vascular Coupling: A Comparison With Atenolol (CENTRAL Study)

Journal

JOURNAL OF CLINICAL HYPERTENSION
Volume 13, Issue 12, Pages 917-924

Publisher

WILEY
DOI: 10.1111/j.1751-7176.2011.00549.x

Keywords

-

Funding

  1. GlaxoSmithKline

Ask authors/readers for more resources

Blood pressure (BP) characteristics, such as central aortic pressure and arterial stiffness, independently predict cardiovascular events. The effects of pharmacologically dissimilar beta-blockers on these properties have not been fully elucidated. Patients with essential hypertension and without significant concomitant cardiovascular disease were randomly assigned to controlled-release carvedilol, force-titrated to 80 mg (n=22), or atenolol, force-titrated to 100 mg (n=19); each was given once daily for 4 weeks. Baseline characteristics were similar. At the end of week 4, atenolol and carvedilol reduced central and brachial systolic and diastolic BP to a similar extent. Central augmentation index was increased in atenolol-treated patients but not carvedilol-treated patients (atenolol 4.47% vs carvedilol -0.68%; P=.04). Mean augmented central aortic pressure increased slightly during atenolol treatment (+1.1 mm Hg) but decreased slightly during carvedilol treatment (-1.1 mm Hg), although the difference in these changes was not statistically significant (P=.23). Pulse pressure amplification was reduced more with atenolol at week 4 (atenolol) 10.7% vs carvedilol) 1.8%; P=.02). Therefore, we conclude that carvedilol results in more favorable pulse pressure amplification and augmentation index by increasing arterial compliance and reducing the magnitude of wave reflection, respectively, compared with atenolol. J Clin Hypertens ( Greenwich). 2011; 13: 917-924. (C) 2011 Wiley Periodicals, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Endocrinology & Metabolism

Are novel glucose-lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment

Huilin Tang, Stephen E. Kimmel, Inmaculada Hernandez, Maria M. Brooks, Kenneth Cusi, Steven M. Smith, Weilong Shi, Almut G. Winterstein, Jared W. Magnani, Jingchuan Guo

DIABETES OBESITY & METABOLISM (2022)

Article Peripheral Vascular Disease

Evaluation of a Beta-Blocker-Edema-Loop Diuretic Prescribing Cascade: A Prescription Sequence Symmetry Analysis

Scott Martin Vouri, Earl J. Morris, Xinyi Jiang, Ann-Kathrin Hofer, Stephan Schmidt, Carl Pepine, Almut G. Winterstein, Steven M. Smith

Summary: This study assessed the use of loop diuretics following beta-blocker initiation and found that there was an excess use of loop diuretics, which could not be fully explained by secular trends or hypertension progression.

AMERICAN JOURNAL OF HYPERTENSION (2022)

Editorial Material Cardiac & Cardiovascular Systems

Acetaminophen-Induced Hypertension: Where Have All the Safe Analgesics Gone?

Steven M. Smith, Rhonda M. Cooper-DeHoff

CIRCULATION (2022)

Article Urology & Nephrology

Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis

Haesuk Park, Raj Desai, Xinyue Liu, Steven M. Smith, Juan Hincapie-Castillo, Linda Henry, Amie Goodin, Saraswathi Gopal, Carl J. Pepine, Raj Mohandas

Summary: The study found that changes in policies led to a significant decrease in erythropoietin-stimulating agent use and an increase in blood transfusion use. Patient hemoglobin levels decreased, but the risks of cardiovascular events, stroke, mortality, and heart failure decreased, while the risk of acute myocardial infarction increased.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

Article Endocrinology & Metabolism

Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials

Huilin Tang, Stephen E. Kimmel, Steven M. Smith, Kenneth Cusi, Weilong Shi, Matthew Gurka, Almut G. Winterstein, Jingchuan Guo

Summary: This study aims to compare the cardiorenal benefits of SGLT2 inhibitors and GLP-1 receptor agonists between White and Asian populations, as well as between the two agents in Asian patients. The findings suggest that there are comparable cardiorenal benefits of these drugs in both populations.

DIABETES CARE (2022)

Article Pharmacology & Pharmacy

Norepinephrine reuptake inhibitors and risk of antihypertensive treatment intensification and major adverse cardiovascular events in patients with stable hypertension and depression

Raj Desai, Haesuk Park, Joshua D. Brown, Rajesh Mohandas, Steven M. Smith

Summary: This study aimed to compare the risk of antihypertensive treatment intensification (TI) and major adverse cardiovascular events (MACE) in patients with stable hypertension and depression who initiated serotonin norepinephrine reuptake inhibitors (SNRI) versus selective serotonin reuptake inhibitors (SSRIs). The study found no difference in the risk of TI and MACE between SNRI and SSRI initiation.

PHARMACOTHERAPY (2022)

Article Anthropology

Racial and ethnic differences in blood pressure before and after the 2016 United States general election

Andrew Y. Hwang, Michelle Cardel, Steven M. Smith

Summary: This study examined population-level changes in blood pressure following the 2016 U.S. presidential election and found differences in blood pressure changes among different racial and ethnic groups. Non-Hispanic Asian participants showed increased systolic blood pressure, while non-Hispanic Black and Mexican American participants showed increased diastolic blood pressure, possibly associated with gender differences.

AMERICAN JOURNAL OF HUMAN BIOLOGY (2022)

Article Pharmacology & Pharmacy

Impact of Piperacillin-Tazobactam Dosing in Septic Shock Patients Using Real-World Evidence: An Observational, Retrospective Cohort Study

John M. Allen, Devi Surajbali, Dalena Q. Nguyen, Jolanta Kuczek, Maithi Tran, Brianna Hachey, Carinda Feild, Bethany R. Shoulders, Steven M. Smith, Stacy A. Voils

Summary: This article investigates the rate and impact of piperacillin-tazobactam dose adjustment in early phase septic shock patients. The study found that dose reduction is associated with worsened clinical outcomes.

ANNALS OF PHARMACOTHERAPY (2023)

Article Geriatrics & Gerontology

Continued potassium supplementation use following loop diuretic discontinuation in older adults: An evaluation of a prescribing cascade relic

Grace Hsin-Min Wang, Earl J. Morris, Steven M. Smith, Jesper Hallas, Scott M. Vouri

Summary: Based on the analysis of Medicare data, we found that it is common for older adults to receive potassium supplementation simultaneously or after loop diuretic initiation, and some patients continue to use potassium even after discontinuing the loop diuretic. This phenomenon, known as relics, highlights the need for clinicians to be aware of and address unnecessary drug use.

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2023)

Article Cardiac & Cardiovascular Systems

Initial Antihypertensive Regimens in Newly Treated Patients: Real World Evidence From the OneFlorida plus Clinical Research Network

Steven M. M. Smith, Almut G. G. Winterstein, Matthew J. J. Gurka, Marta G. G. Walsh, Shailina Keshwani, Anne M. M. Libby, William R. R. Hogan, Carl J. J. Pepine, Rhonda M. M. Cooper-DeHoff

Summary: This study reveals significant variation in initial antihypertensive prescribing among new users, highlighting a gap between current guideline recommendations and real-world implementation in early hypertension care.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2023)

Editorial Material Cardiac & Cardiovascular Systems

Medication Adherence-Still the Holy Grail

Rhonda M. M. Cooper-DeHoff, Steven M. M. Smith

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2023)

Article Public, Environmental & Occupational Health

High-throughput screening for prescribing cascades among real world statin initiators

Scott M. Vouri, Earl J. Morris, Marta Walsh, Jessica Agalliu, Alyssa Dempsey, Leonie Hochleitner, Matthew R. Muschett, Stephan Schmidt, Carl J. Pepine, Steven M. Smith

Summary: This study aimed to comprehensively assess prescribing cascades related to statin medications. The results identified potential prescribing cascades, including laxatives, analgesics, and cephalosporins. These findings are important for reducing the occurrence of prescribing cascades.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2023)

Article Pharmacology & Pharmacy

Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction

Munaza Riaz, Steven M. Smith, Eric A. Dietrich, David E. Winchester, Jingchuan Guo, Haesuk Park

Summary: This study found that the use of empagliflozin was associated with a decreased risk of heart failure-related and all-cause hospitalizations compared to canagliflozin or dapagliflozin.

PHARMACOTHERAPY (2023)

Article Pharmacology & Pharmacy

Modifiable statin characteristics associated with potential statin-related prescribing cascades

Grace Hsin-Min Wang, Earl Morris, Scott M. Vouri, Shailina Keshwani, Stephan Schmidt, Carl J. Pepine, Steven M. Smith

Summary: This study aims to identify modifiable statin characteristics associated with lower risk of prescribing cascades. The results show that compared to low-intensity statins, moderate- or high-intensity statins and the choice of individual statin agents are associated with increased risk of prescribing cascades.

PHARMACOTHERAPY (2023)

Article Pharmacology & Pharmacy

Risk of Fractures With Concomitant Use of Calcium Channel Blockers and Selective Serotonin Reuptake Inhibitors

Raj Desai, Steven Smith, Rajesh Mohandas, Joshua Brown, Haesuk Park

Summary: This study found that concomitant use of calcium channel blockers (CCBs) and selective serotonin reuptake inhibitors (SSRIs) was associated with an increased risk of fractures compared to CCB-only users. However, there was no difference in fracture risk between concomitant users of CCBs with CYP3A4-inhibiting SSRIs and CCBs with non-CYP3A4 inhibiting SSRIs.

ANNALS OF PHARMACOTHERAPY (2023)

No Data Available